

Chairs:
Pietro Lampertico and Heiner Wedemeyer

program

OCTOBER
11-12, 2024
MILAN, ITALY

Fondazione Cariplo - Conference Center

Delta *ure*

3rd International Meeting

with the endorsement of



UNIVERSITÀ
DEGLI STUDI
DI MILANO



EASL™ The Home of
Hepatology



The Stephan Urban
Foundation



also online  www.deltacure2024.com

Dear Colleagues and Friends,

It's a great pleasure to announce the final scientific program of the 3rd Edition of **Delta Cure International Meeting** to be held in **Milan, Italy, on October 11-12, 2024.**

We are organizing an exciting meeting in a hospitable environment that will certainly favor an important scientific exchange. Infact, the **Delta Cure Meeting** will review the last evidences in terms of virology, pathogenesis and epidemiology, diagnosis and endpoints.

Two full sessions will be dedicated to thoughtfully debate the most recent advances in terms of current and new antiviral treatments. We will also discuss suggestions for treatment algorithms which will be included in a meeting report to be published in a leading journal of the field. The Faculty will involve an excellent panel of Experts who will guide the attendees through all the challenges of this disease. In particular, we want to encourage young scientists to contribute in topical scientific sessions by submitting abstracts.

Milan is a vibrant cosmopolitan center where the various cultures of northern European and Mediterranean countries merge; it has a lot to offer: art museums, history, opera (La Scala), music, fashion, design, culinary delights and business opportunities. Milan is easy to reach by all means of transport, but is one of the most accessible cities in Europe in terms of air links through 3 international airports (Malpensa, Linate and Orio al Serio).

Furthermore, Milan has the largest public transport network which let people travel around the city urban community and the region easily and quickly.

This event will give you the opportunity to focus on the newest scientific trends in our field in an atmosphere of Italian hospitality and the Italian expression of European Union.

We are sure that - forty-five years after the discovery of HDV - this Meeting will shed new exciting lights on the management of this difficult-to-treat disease.

Looking forward to seeing you in Milan!

The Chairs
Pietro Lampertico and Heiner Wedemeyer



CHAIRS

Pietro Lampertico - IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan (Italy)

Heiner Wedemeyer - Hannover Medical School, Hannover (Germany)

SPEAKERS

Kosh Agarwal - King's College Hospital, London (UK)

Soo Aleman - Karolinska University Hospital, Huddinge (Sweden)

Lena Allweiss - University Medical Center Hamburg-Eppendorf, Hamburg (Germany)

Maria Paola Anolli - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy)

Tarik Asselah - Hôpital Beaujon, APHP, Clichy, France, University of Paris, Paris (France)

Thomas Berg - University Hospital Leipzig, Leipzig (Germany)

Maurizia Brunetto - Azienda Ospedaliero Universitaria Pisana, Università degli Studi di Pisa, Pisa (Italy)

Maria Buti - Hospital General Universitari Valle Hebron, Barcelona (Spain)

Isabelle Chemin - Cancer Research Center, Lyon (France)

Harel Dahari - Loyola University Medical Center, Chicago (USA)

Maura Dandri - University Medical Center Hamburg-Eppendorf, Hamburg (Germany)

Elisabetta Degasperi - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy)

Gianpiero D'Offizi - Istituto Nazionale di Malattie Infettive "Lazzaro Spallanzani", Rome (Italy)

Rafael Esteban - Hospital Universitario Val d'Hebron, Universidad Autónoma de Barcelona, Barcelona (Spain)

Hélène Fontaine - Assistance Publique Hôpitaux de Paris, Paris (France)

Saeed Sadiq Hamid - The Aga Khan University, Karachi (Pakistan)

Mathias Jachs - Medical University of Vienna, Vienna (Austria)

Helenie Kefalakes - Hannover Medical School, Hannover (Germany)

Massimo Levrero - IHU Lyon - Institute of Hepatology of Lyon, Lyon (France)

Julie Lucifora - Centre International de Recherche en Infectiologie, Lyon (France)

Niklas Luhmann - WHO Headquarters, Geneva (Switzerland)

Erkin Musabaev - Research Institute of Virology, Tashkent (Uzbekistan)

George Papatheodoridis - "Laiko" General Hospital of Athens, Athens (Greece)

Nancy Reau - Rush University Medical Center, Chicago (USA)

Francesco Paolo Russo - University Hospital Padova, Padova (Italy)

Lisa Sandmann - Hannover Medical School, Hannover (Germany)

Barbara Testoni - Cancer Research Center of Lyon, Lyon (France)

Stephan Urban - Heidelberg University Hospital, Heidelberg (Germany)

Cihan Yurdaydin - Koç University Medical School, Istanbul (Turkey)

ORAL PRESENTERS

Soo Aleman - Karolinska University Hospital, Huddinge (Sweden)

Tarik Asselah - Hôpital Beaujon, APHP, Clichy, France, University of Paris, Paris (France)

Lorenza Di Marco - University of Modena and Reggio Emilia, Modena (Italy)

Joachim Lupberger - University of Strasbourg, Strasbourg (France)

SCIENTIFIC SECRETARIAT AND ABSTRACT REVIEWERS

Elisabetta Degasperi - IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan (Italy)

Lisa Sandmann - Hannover Medical School, Hannover (Germany)



OCTOBER 11, 2024

Opening Session

11.20 - 11.30 Welcome by Chairs *P. Lampertico and H. Wedemeyer*

WHO SESSION **Hepatitis Delta: making a difference in low- and middle-income countries**

Moderators: F.P. Russo and H. Wedemeyer

11.30 - 11.40 Updated WHO HBV guidelines and recommendations for testing and diagnosis for HDV
N. Luhmann

11.40 - 11.50 Diagnostics for HDV: what we have and what we need for improving diagnosis
in low-and-middle income countries *I. Chemin*

11.50 - 12.00 Hepatitis Delta epidemiology and experiences with HDV diagnosis and reflex testing
in Uzbekistan *E. Musabaev*

12.00 - 12.15 HDV diagnosis and treatment in Pakistan and the way forward for LMICs *S.S. Hamid*

12.15 - 12.30 Panel discussion

12.30 - 13.30 Light Lunch and DZIF Poster Session

SESSION 1 **Virology and Pathogenesis**

Moderators: M. Dandri and J. Lucifora

13.30 - 13.50 Virology: the latest insights *S. Urban*

13.50 - 14.10 Pathogenesis: insights from liver biopsies *L. Allweiss*

14.10 - 14.30 Are immune responses important in HDV infection? *H. Kefalakes*

14.30 - 14.50 New HBV biomarkers: any role in HDV? *B. Testoni*

14.50 - 15.00 Oral presentation

Integrative transcriptomics and epigenomics reveals a viral footprint of chronic HDV infection
in HBV co-infected chimeric livers *J. Lupberger*

15.00 - 15.20 Discussion

15.20 - 15.50 Coffee Break and DZIF Poster Session



SESSION 2 Diagnosis, Staging, HCC risk and antiviral therapy

Moderators: S. Aleman and R. Esteban

- 15.50 - 16.10 HDV-RNA assays: performances and clinical challenges *M.P. Anolli*
16.10 - 16.30 Fibroscan and other non-invasive markers *L. Sandmann*
16.30 - 16.50 PegIFN+NUC: predictors of response *M. Brunetto*
- 16.50 - 17.00 Oral presentation
Hepatitis delta virus (HDV) replication through HBV integrants in HCC recurrence
after liver transplantation *L. Di Marco*
- 17.00 - 17.20 Discussion

SESSION 3 Current and new antiviral treatments I

Moderators: G. Papatheodoridis and N. Reau

- 17.20 - 17.40 Bulevirtide mono and combo in clinical trials *H. Wedemeyer*
17.40 - 17.55 Bulevirtide in EU: SAVE-D study update *E. Degasperis*
17.55 - 18.10 Bulevirtide in France: multicenter study update *H. Fontaine*
18.10 - 18.25 Bulevirtide for decompensated cirrhosis *M. Jachs*
- 18.25 - 18.35 Oral presentation
Efficacy and safety of BLV monotherapy for chronic hepatitis delta: post treatment results
through 24 weeks after the end of treatment from an interim analysis of a randomized
Phase 3 study MYR301 *S. Aleman*
- 18.35 - 19.00 Discussion
- 19.00 - 19.30 State of the Art Lecture and Prize: "My journey with HDV" *C. Yurdaydin*
(presented by H. Wedemeyer)
- 19.30 - 20.00 Transfer to the Dinner venue *(walking distance)*
20.00 - 22.30 Aperero and Dinner



OCTOBER 12, 2024

08.30 - 08.50 Opening remarks Day 2 *P. Lampertico and H. Wedemeyer*

SESSION 4 **Current and new antiviral treatments II**

Moderators: T. Berg and M. Buti

08.50 - 09.10 Bulevirtide in HIV coinfecting patients *G. D'Offizi*

09.10 - 09.30 Can we stop Bulevirtide? Lessons learned from viral kinetics modelling *H. Dahari*

09.30 - 09.50 What have we learned from the Lonafarnib and pegIFN lambda trials? *T. Asselah*

09.50 - 10.10 New antivirals for HDV, phase II studies *K. Agarwal*

10.10 - 10.30 What can we learn from HBV trials for HDV cure? *M. Levrero*

10.30 - 10.40 Oral presentation

Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the Phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants *T. Asselah*

10.40 - 11.00 Discussion

11.00-11.30 Coffee Break and DZIF Poster Session

SESSION 5 **Round Table Discussion**

Moderators: P. Lampertico and H. Wedemeyer

11.30 - 12.30 Hot topics in HDV management.

- **For Institutions and Patient Associations:** *I. Gardini, EpaC; M. Korenjak, ELPA; N. Luhmann, WHO*
- **For Pharma and Diagnostics:** *M. Mertens, Gilead Sciences; A. Reinhardt, Roboscreen; K. Rottengatter, Altona Diagnostics; N. Shulman, Bluejay Therapeutics; C. Voitenleitner, Roche Diagnostics*
- **For Academia:** *Delta Cure Faculty*

12.30 - 12.45 Closing remarks *P. Lampertico and H. Wedemeyer*

12.45 - 13.45 Farewell Lunch



POSTER AREA 1 - DIAGNOSIS, STAGING, HCC RISK AND ANTIVIRAL THERAPY

P1 Nearly One-Third of Veterans with Hepatitis Delta Virus Infection in the United States Have Already Developed Cirrhosis or Hepatocellular Carcinoma at Time of Diagnosis

R.J. Wong^{1,2}, Z. Yang², J. Lim³, J.H. Jou^{4,5}, R. Cheung^{1,2}

¹Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA; ²Gastroenterology and Hepatology Section, Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA, USA; ³Section of Digestive Diseases and Yale Liver Center, Yale University School of Medicine, New Haven, Connecticut; ⁴Division of Gastroenterology and Hepatology, Department of Medicine, Oregon Health & Science University Hospital Portland OR; ⁵Division of Gastroenterology and Hepatology, Department of Medicine, Portland VA Medical Center Portland OR

P2 Quantification of plasma HDV RNA in untreated and bulevirtide-treated patients with CHD: a comparison between robogene 2.0, Eurobioplex and altostar

M.P. Anolli¹, S. Uceda Renteria², E. Degasperis¹, F. Facchetti¹, D. Sambarino¹, M. Borghi¹, R. Perbellini¹, R. Soffredini¹, S. Monico¹, A. Callegaro², P. Lampertico^{1,3,4}

¹Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ²Microbiology and Virology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ³CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ⁴D-SOLVE consortium, an EU Horizon Europe funded project (No 101057917)

P3 Value and kinetics of virological markers in the natural course of chronic hepatitis D virus infection

L. Sandmann^{1,2,3}, V. Ohlendorf¹, A. Ehrenbauer¹, B. Bremer¹, A.R.M. Kraft^{1,3,4,5}, M. Cornberg^{1,2,3,4,5}, K. Deterding¹, H. Wedemeyer^{1,2,3,4}, B. Maasoumy^{1,4}

¹Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Germany; ²D-SOLVE consortium, an EU Horizon Europe funded project; ³Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany; ⁴German Center for Infection Research (DZIF), Hannover/Braunschweig, Germany; ⁵Centre for Individualised Infection Medicine (CiiM), a joint venture between Helmholtz-Centre for Infection Research and Hannover Medical School, Hannover, Germany

P4 Hepatitis delta virus (HDV) replication through HBV integrants in HCC recurrence after liver transplantation

L. Di Marco^{1,2}, N. De Maria³, A. Pivetti³, A. Colecchia³, A. Romanzi³, A. Spallanzani¹, G. Guaraldi⁴, G. Dolci⁴, G. Ciusa⁵, F. Di Benedetto⁶, P. Magistri⁶, S. Di Sandro⁶, E. Degasperis⁷, M.P. Anolli⁷, P. Lampertico⁷, D. Giosa⁸, D. Lombardo⁹, G. Raimondo⁹, T. Pollicino⁹

¹Department of Oncology and Hematology, Oncology Unit, University Hospital of Modena and Reggio Emilia, University of Modena and Reggio Emilia, Modena, 41124, Italy; ²Clinical and Experimental Medicine Program, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy; ³Chimomo Department, Gastroenterology Unit, University Hospital of Modena and Reggio Emilia, University of Modena and Reggio Emilia, 41124 Modena, Italy; ⁴Department of Infectious Diseases, University Hospital of Modena and Reggio Emilia, University of Modena and Reggio Emilia, Modena, 41124, Italy; ⁵Infectious Diseases Unit, ARNAS "Civico-Di Cristina-Benfratelli", Palermo, Italy; ⁶Hepato-pancreato-biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, 41124, Italy; ⁷Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ⁸Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy; ⁹Department of Internal Medicine, University Hospital of Messina, Messina, Italy

P5 Development and implementation of an hepatitis D detection and linkage to care program in Catalonia. Preliminary results.

A. Palom^{1,2}, A. Rando-Segura^{1,2}, L. Calatayud Samper³, G. Fernandez Rivas⁴, A. Sellés Sanchez⁵, S. Mormeneo Bayo⁶, D. Pérez del Campo⁷, M.M.O. Perez Moreno⁸, J. Ayats⁹, D. Taberner¹⁰, J. Castellote³, R.M. Morillas⁴, J.C. Quer⁵, C. Aracil Blanch⁶, C. Lopez⁷, D. Salazar⁸, A. Marco¹⁰, M. Buti^{1,2}

¹Hospital Universitari Vall d'Hebron, Barcelona, Spain; ²Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; ³Hospital Universitari de Bellvitge, Barcelona, Spain; ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain; ⁵Hospital Universitari Joan XXIII de Tarragona, Tarragona, Spain; ⁶Hospital Universitari Arnau de Vilanova, Lleida, Spain; ⁷Hospital Universitari Doctor Josep Trueta, Girona, Spain; ⁸Hospital Universitari Verge de la Cinta de Tortosa, Tarragona, Spain; ⁹Microbiology Area of the Clinical Laboratories Directorate, Catalan Institute of Health (ICS), Barcelona, Spain; ¹⁰Penitentiary Health Program, Catalan Institute of Health (ICS), Barcelona, Spain

P6 THE WHO HDV RNA International Standard does not reflect variability of real-world samples

B. Bremer¹, K. Deterding¹, K. Portl¹, B. Gey², C. Früchtel², A. Reinhardt², I. Lachmann², M. Cornberg^{1,3,4,5,6}, H. Kefalakes^{3,4,5}, B. Maasoumy^{1,5}, H. Wedemeyer^{1,3,4,5}, L. Sandmann^{1,3,4}

¹Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover; ²Roboscreen GmbH, Leipzig; ³D-SOLVE consortium, an EU Horizon Europe funded project (No 101057917); ⁴Excellence Cluster RESIST Hannover Medical School, Hannover; ⁵German Center for Infection Research (DZIF), Hannover/Braunschweig; ⁶Centre for Individualised Infection Medicine, Helmholtz Centre for Infection Research/Hannover Medical School, Hannover

P7 Bulevirtide: a success case after pegINF α failure

A. Carraro¹, R. Marocco¹, B. Kertusha¹, G. Mancarella¹, L. Ansaldo¹, L. Fondaco¹, S. De Maria¹, S. Corazza¹, A. Gasperin¹, A. Grimaldi¹, C. Del Borgo¹, M. Lichtner²

¹Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome Polo Pontino, Latina, Italy; ²Department of NESMOS, Sapienza University of Rome, Rome, Italy



- P8 The prevalence and characteristics of hepatitis B/D in 48,522 HBsAg tested individuals in Mongolia**
G. Jargalsaikhan^{1,2} and H. Kamal³, S.n Enkhтайван^{1,2}, D. Bruce⁴, B. Dashtseren^{1,2}, T. Ulziyadbrakh^{1,2}, M. Batkhuu^{1,2}, P. Bat-Ulzii^{1,2}, S. Byambabaatar^{1,2}, N. Dashdorj^{1,2} and S. Aleman³
¹The Liver Center, Ulaanbaatar, Mongolia; ²ONOM Foundation, Ulaanbaatar, Mongolia; ³The department of Infectious Diseases, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden; ⁴SDS Life Science statistical consultancy, Stockholm, Sweden
- P9 Validation of Streamlined serodiagnosis of hepatitis delta virus**
A. Dashdorj^{1,2}, K. An³, N. Ariungerel⁵, S. Han³, G. Choi³, S. Ah Kim⁴, T.H. Kim³, M. Chung⁴, O. Oidosambuu⁵, B. Ochirsum², S. Enkhтайван², Saruul Enkhjargal⁵, P. Bat-Ulzii², E. Ochirbat², N. Dashdorj^{1,2}, N. Dashdorj^{1,2} N.J. Cho⁶
¹Onom Foundation, Ulaanbaatar; ²The Liver Center, Ulaanbaatar; ³Department of Research and Development, Anyang; ⁴Department of Chemical Engineering, Hongik University, Seoul; ⁵Laboratory of Genetic Engineering, NUM, Ulaanbaatar; ⁶School of Materials Science and Engineering, Nanyang Technological University, Singapore
- P10 Limited use of established risk scores for the prediction of hepatocellular carcinoma in patients with chronic hepatitis D virus infection**
R. Iker^{1,2}, A. Wranke^{1,2}, H. Schneider¹, H. Wedemeyer^{1,2,3,4}, H. Kefalakes^{1,2,3,4}, L. Sandmann^{1,3,4}
¹Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; ²German Center for Infection Research (DZIF), Hannover-Braunschweig Site, Germany; ³D-SOLVE: EU-funded Network on individualized management of hepatitis D, Hannover, Germany; ⁴RESIST Cluster of Excellence, Hannover Medical School, Hannover, Germany
- P11 Is there a Hepatitis Delta Virus variant in West Africa, not detected by current serological diagnostic tests?**
P. Hamouda¹, A. Gerber^{1,2}, A. Ramirez Mena³, V. Delagarde^{1,2}, B. Wembulua Shinga³, M. Seydi³, N. Fatou Ngom³, O. Ndiaye³, E. Gordien^{1,2}, S. Brichler^{1,2}, G. Wandeler³, F. Le Gal^{1,2}
¹Centre nationale de référence des Hépatites virales B, C et Delta, Laboratoire de Microbiologie clinique, Hôpital Avicenne, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Paris Cité, Bobigny, France; ²INSERM, U955 équipe 18, Créteil, France; ³Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Fann, Dakar, Sénégal
- P12 Novel anti-HDV therapies require reliable quantification of plasma HDV RNA: A European multicenter study**
A. Reinhardt¹, E. Stelz², J. Kress³, A. Olivero⁴, P. Lampertico⁵, A. Heim⁶, S. Aberle⁷, H. Wedemeyer⁸, A. Berger¹, B. Gey⁹, C. Früchtel⁹, H.H. Kessler²
¹Institute of Medical Virology, Goethe University Frankfurt, Germany; ²Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Austria; ³Section of Molecular Virology, Paul-Ehrlich-Institute, Langen, Germany; ⁴Gastroenterology and Hepatology Department, "San Giovanni Battista" Hospital and Department of Internal Medicine, University of Torino, Italy; ⁵Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ⁶Hannover Medical School, Institute of Virology, Hannover, Germany; ⁷Center for Virology, Medical University of Vienna, Vienna, Austria; ⁸Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; ⁹Roboscreen GmbH, Leipzig, Germany
- P13 The asymmetry of the liver and spleen stiffness measures between patients with chronic hepatitis B and D reflects important clinic-pathologic differences**
F. Damone¹, P. Colombatto¹, A. Pinna¹, G. Ricco¹, D. Cavallone¹, G. Petralli¹, L. De Stefano², B. Coco¹, L. Surace¹, V. Romagnoli¹, F. Oliveri¹, F. Bonino³ and M. R. Brunetto^{1,2}
¹Hepatology Unit, University Hospital of Pisa, Pisa, Italy; ² Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; ³Institute of Biostructure and Bioimaging, National Research Council, Naples, Italy
- P14 Diagnostic performances of different HDV RNA quantification assays used in clinical practice in Italy: results from a national quality control multicenter study**
L. Piermatteo¹, R. Salpini¹, G.P. Caviglia², A. Bertoli^{3,4}, M.R. Brunetto^{5,6}, B. Bruzzone⁷, A. Callegaro⁸, C. Caudai⁹, D. Cavallone^{5,6}, L. Chessa¹⁰, F. Coghe¹⁰, N. Coppola¹², N. Cuomo¹³, S. D'Anna¹, M. Di Stefano¹⁴, L. Duca³, F. Facchetti¹⁵, C. Farina¹⁶, D. Ferraro¹⁷, E. Franchin¹⁸, D. Francisci¹⁹, S. Galli²⁰, A.R. Garbuglia²¹, W. Gennari²², V. Ghisetti²³, P. Lampertico^{15,24}, N. Marascio²⁵, S. Menzo²⁶, V. Micheli²⁷, G. Niro²⁸, A. Olivero², P. Paba⁴, C.I. Palermo²⁹, O. Palmieri²⁸, S. Paolucci³⁰, M. Pisaturo¹², T. Pollicino³¹, G. Raffa³¹, G. Torre¹, O. Turriziani³², S. Uzzau³³, M. Vatteroni³⁴, M. Zazzi³⁵, A. Craxi¹⁷, F. Ceccherini-Silberstein³, V. Svicher¹ on behalf of the Virology Italian Network Vironet C
¹Department of Biology, University of Rome "Tor Vergata", Rome, Italy; ²Department of Medical Sciences, University of Turin, Turin, Italy; ³Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy; ⁴Unit of Virology, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy; ⁵Dept of Clinical and Experimental Medicine, University of Pisa; ⁶Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Pisa University Hospital, Italy; ⁷Department of Health Sciences, University of Genoa, Genoa, Italy; ⁸Medicina di Laboratorio, ASST Bergamo Est, Bergamo, Italy; ⁹Microbiology and Virology Unit, Siena University Hospital, Siena, Italy; ¹⁰Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; ¹¹Laboratory Clinical Chemical Analysis and Microbiology, University Hospital of Cagliari, Cagliari, Italy; ¹²Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Caserta, Italy; ¹³Microbiology and Virology Unit, Domenico Cotugno Hospital, Naples, Italy; ¹⁴Clinical and Surgical Sciences, Section of Infectious Diseases, University Hospital "Riuniti" of Foggia, Foggia, Italy; ¹⁵Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ¹⁶Microbiology and Virology Unit, ASST "Papa Giovanni XXIII", Bergamo, Italy; ¹⁷Section of Microbiology and Clinical Microbiology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy; ¹⁸Department of Molecular Medicine, University of Padova, Padova, Italy; ¹⁹Infectious diseases laboratory, Santa Maria della Misericordia Hospital, Perugia, Italy; ²⁰Operative Unit of Clinical Microbiology, IRCCS S. Orsola-Malpighi University

Hospital, Bologna, Italy; ²¹Laboratory of Virology, "Lazzaro Spallanzani" National Institute for Infectious Diseases, IRCCS, Rome, Italy; ²²Molecular Microbiology and Virology Unit, Department of Laboratory Medicine and Pathological Anatomy, Azienda Ospedaliero Universitaria di Modena, Modena, Italy; ²³Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy; ²⁴CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ²⁵Unit of Clinical Microbiology, Department of Health Sciences, "Magna Graecia" University, Catanzaro, Italy; ²⁶Department of Biomedical Sciences and Public Health, Università Politecnica Delle Marche, Ancona, Italy; ²⁷Laboratory of Clinical Microbiology, Virology and Bioemergencies, Ospedale Sacco, Milan, Italy; ²⁸Division of Gastroenterology and Endoscopy, Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy; ²⁹Policlinico Universitario "Gaspare Rodolico", Catania, Italy; ³⁰Microbiology and Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; ³¹Department of Clinical and Experimental Medicine, University Hospital "G. Martino" Messina, Messina, Italy; ³²Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; ³³Department of Biomedical Sciences, University of Sassari, Sassari, Italy; ³⁴Virology Unit, Pisa University Hospital, Pisa, Italy; ³⁵Department of Medical Biotechnology, University of Siena, Siena, Italy

P15 Hepatitis Delta Virus RNA quantification: a story about fruitful collaboration between private company and academic laboratory

A. Gerber¹, M. Breuer², V. Delagarde¹, K. Rottengatter², S. Dziri¹, E. Vincent², E. Gordien¹, F. Le Gal¹, S. Briclher¹
¹Avicenne Hospital, Virology Unit, French National Reference Centre for HDV, Bobigny, France; ²Altona Diagnostics, Hamburg, Germany

P16 Clinical evaluation of the Altostar HDV RT-PCR Kit 1.5

J.C. Eichholz¹, B. Bremer¹, H. Wedemeyer^{1,2,3,4}, B. Maasoumy^{1,2}, L. Sandmann^{1,3,4}
¹Department of Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany; ²German Center for Infection Research (DZIF), Hannover/Braunschweig, Germany; ³D-SOLVE consortium, an EU Horizon Europe-funded project (no. 101057917); ⁴Excellence Cluster RESIST, Hannover Medical School, Hannover, Germany

P17 Hepatitis Delta infection in individuals living with HIV – multicentric portuguese study

C. Valente¹, R. Carvalho¹, R. Lino², D. Alves¹, R. Aleixo¹, C. Antunes³, M. Ferreira³, C. Pineiro², P. Vasques⁴, I. Casella⁴, C. Azevedo⁵, R. Serrão⁵, A.C. Miranda³, K. Mansinho³, T. Teixeira⁵
¹Infectious Diseases, ULS Coimbra, Coimbra, Portugal; ²Infectious Diseases, ULS São João, Porto, Portugal; ³Infectious Diseases, H Egas Moniz, ULS Lisboa Ocidental, Lisboa, Portugal; ⁴Infectious Diseases, ULS Arrábida, Setúbal, Portugal; ⁵Infectious Diseases, ULS Gaia Espinho, Gaia, Portugal

P18 HDV RNA assay sensitivity is critical for determining a correct outcome during Bulevirtide antiviral therapy

I. Carey¹, M. Anderson², Z. Cargill¹, S. Shah¹, J. Lok¹, G. Cloherty², G. Dusheiko¹, K. Agarwal¹
¹Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, SE5 9RS, United Kingdom; ²Department on Infectious Diseases, Abbott Diagnostics, Abbott Park, Chicago, IL 60064, United States of America

P19 Treatment with pegIFN α inhibits cell division-mediated spread of HDV in a humanized mouse model supporting cell proliferation

A. Volmari^{1,2}, T. Volz^{1,2}, L. Allweiss^{1,2}, M. Luetgehetmann^{2,3}, S.P. Fletcher⁴, M.M. Holdorf⁴, R.C. Muench⁴, M. Dandri^{1,2}
¹Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ²German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems site, Germany; ³Institute of Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ⁴Gilead Sciences, Foster City, California, United States of America

P20 Chronic delta hepatitis without efficient treatment poses a greater risk for hepatocellular cancer development than chronic hepatitis B with efficient treatment

O. Keskin¹, C. Kalkan², M. Gumussoy², E. Yurdcu², Z. Melekoglu Ellik², Y. Yilmaz², H. Sahin¹, B. Ozturk¹, Y. Emre Parlar¹, R. Idilman², M. Bozdayi², C. Yurdaydin^{2,3}
¹Hacettepe University School of Medicine; ²Ankara University School of Medicine; ³Koc University School of Medicine

P21 Complexities of Hepatitis Delta Virus Testing in a High HBV Prevalence Setting in London

N. Kokkinos¹, T. Kandaswamy Murugesan¹, A. Millar¹, G. Kerry¹, K.N. Wai-Mon¹, E. Nastouli², A.M. Geretti^{1,3}
¹North Middlesex University Hospital, London; ²University College Hospital, London; ³University of Rome Tor Vergata, Rome

P22 High frequency of liver cirrhosis in European patients with hepatitis D: Data from a large multicentre study (D-SOLVE and HDV-1000 consortia)

A. Wrانke^{1,2,3}, H. Kama^{3,4,5}, Z. Cargill⁶, M. Radu^{3,7}, E. Degasperis^{3,8,9}, K. Lindahl^{3,4,5}, P. Dörge^{1,3,10}, J. Kahlhöfer^{1,3,10,11}, K. Agarwal⁶, P. Lampertico^{3,8,9}, F.A. Caruntu^{3,7}, H. Wedemeyer^{1,2,3,12}, S. Aleman^{3,4,5}, I. Carey⁶, L. Sandmann^{1,3,12}
¹Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; ²German Center for Infection Research (DZIF), Hannover/Braunschweig, Germany; ³D-SOLVE: EU-funded Network on individualized management of hepatitis D, Germany; ⁴Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden; ⁵Department of Medicine Huddinge, Infectious Diseases, Karolinska Institute, Stockholm, Sweden; ⁶Institute of Liver Studies, King's College Hospital, London, United Kingdom; ⁷Institutul de Boli Infectioase, Bucharest, Romania; ⁸Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ⁹CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ¹⁰German Center for Infection Research (DZIF), HepNet Study-House/German Liver Foundation, Hannover, Germany; ¹¹Centre for Individualized Infection Medicine (CiiM), Helmholtz Centre for Infection Research/Hannover Medical School, Hannover, Germany; ¹²Excellence Cluster RESIST, Excellence Initiative Hannover Medical School, Hannover, Germany



POSTER AREA 2 - CURRENT AND NEW ANTIVIRAL TREATMENTS

P23 Bulevirtide for patients with chronic hepatitis d (CHD) in Italy: a multicenter prospective nationwide real-life study (D-SHIELD)

M.P. Anolli¹, E. Degasperis¹, G. D'Offizi², A. Rianda², A. Loggio³, M. Viganò³, A. Ciancio⁴, Y. Troshina⁴, M.R. Brunetto⁵, B. Coco⁵, S. Zaltron⁶, M. Milella⁷, P. Toniutto⁸, L. Marinaro⁹, A. Gori¹⁰, A. Federico¹¹, T.A. Santantonio¹², G. Verucchi¹³, F. Morisco¹⁴, A. Mangia¹⁵, S. De Nicola¹⁶, M. Maracci¹⁷, A. Romano¹⁸, P. Gatti¹⁹, R. Zampino²⁰, M. Persico²¹, P. Pozzoni²², A. Pellicelli²³, N. Coppola²⁴, F. Pileri²⁵, M. Tonnini²⁶, M. Puoti²⁷, P. Lampertico^{1,28}

¹Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ²Division of Infectious Diseases - Hepatology, Department of Transplantation and General Surgery, Istituto Nazionale per le Malattie Infettive "L. Spallanzani" IRCCS, Rome Italy; ³Gastroenterology, Hepatology and Transplantation Division, ASST Papa Giovanni XXIII, Bergamo, Italy; ⁴Department of Medical Sciences, University of Turin, Gastroenterology Division of Città della Salute e della Scienza of Turin, University Hospital, Turin, Italy; ⁵Department of Clinical and Experimental Medicine, University of Pisa and Hepatology Unit, University Hospital of Pisa, Pisa, Italy; ⁶Infectious Disease Department, Spedali Civili Brescia, Brescia, Italy; ⁷Infectious Diseases Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy; ⁸Hepatology and Liver Transplantation Unit, Academic Hospital, University of Udine, 33100 Udine, Italy; ⁹SCDU Infectious Diseases, Amedeo di Savoia Hospital, ASL Città di Torino, 10149 Turin, Italy; ¹⁰Infectious Disease Unit II, Ospedale Luigi Sacco, ASST Fatebenefratelli Sacco, Milano, Italy; ¹¹Division of Hepatogastroenterology, Department of Precision Medicine, Università della Campania "Luigi Vanvitelli", Naples, Italy; ¹²Department of Medical and Surgical Sciences, Infectious Diseases Unit, University of Foggia, Foggia, Italy; ¹³Department of Medical and Surgical Sciences, Unit of Infectious Diseases, "Alma Mater Studiorum" University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy; ¹⁴Department of Clinical Medicine and Surgery, Diseases of the Liver and Biliary System Unit, University of Naples "Federico II", Naples, Italy; ¹⁵Liver Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy; ¹⁶Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy; ¹⁷Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy; ¹⁸Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine, University of Padova, Padova, Italy; ¹⁹Internal Medicine Unit, Brindisi General Hospital, Brindisi, Italy; ²⁰Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy; ²¹Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy; ²²General Medicine Unit, Presidio Ospedaliero, Azienda Socio Sanitaria Territoriale di Lecco, Lecco, Italy; ²³Liver Unit, San Camillo Hospital, Department of Transplantation and General Surgery, Rome, Italy; ²⁴Department of Mental Health and Public Medicine - Infectious Diseases Unit, University of Campania Luigi Vanvitelli, Naples, Italy; ²⁵Division of Internal Medicine and Center for Hemochromatosis, University of Modena and Reggio Emilia, Modena, Italy; ²⁶Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ²⁷School of Medicine and Surgery University of Milano Bicocca; ²⁸CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

P24 Virological and clinical outcomes of patients with HDV-related cirrhosis treated with bulevirtide monotherapy for up to 96 weeks: a multicenter european study (SAVE-D)

E. Degasperis¹, M.P. Anolli¹, M. Jachs², T. Reiberger², V. De Ledinghen³, S. Metivier⁴, G. D'Offizi⁵, F. di Maria⁵, C. Schramm⁶, H. Schmidt⁶, C. Zöllner⁷, F. Tacke⁷, C. Dietz-Fricke⁸, H. Wedemeyer⁸, M. Papatheodoridis⁹, G. Papatheodoridis⁹, I. Carey¹⁰, K. Agarwal¹⁰, F. Van Bömmell¹¹, M.R. Brunetto¹², M. Cardoso¹³, G. Verucchi¹⁴, A. Ciancio¹⁵, F. Zoulim¹⁶, S. Aleman¹⁷, N. Semmo¹⁸, A. Mangia¹⁹, M.N. Hilleret²⁰, U. Merle²¹, T.A. Santantonio²², N. Coppola²³, A. Pellicelli²⁴, B. Roche²⁵, X. Causse²⁶, L. D'Alteroche²⁷, J. Dumortier²⁸, N. Ganne²⁹, F. Heluwaert³⁰, I. Ollivier³¹, D. Roulot³², M. Viganò³³, A. Loggio³⁴, A. Federico³⁵, F. Pileri³⁶, M. Maracci³⁷, M. Tonnini³⁸, J.P. Arpurt³⁹, K. Berange⁴⁰, E. Billaud⁴¹, S. Pol⁴², A. Gervais⁴³, A. Minello⁴⁴, I. Rosa⁴⁵, M. Puoti⁴⁶, P. Lampertico^{1,47,48}

¹Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ²Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; ³Hepatology Department, Haut-Lévêque Hospital, Bordeaux, France; ⁴Hepatology Unit, CHU Rangueil, 31059, Toulouse, France; ⁵Division of Infectious Diseases - Hepatology, Department of Transplantation and General Surgery, Istituto Nazionale per le Malattie Infettive "L. Spallanzani" IRCCS, Rome Italy; ⁶Department of Gastroenterology, Hepatology and Transplant Medicine, Medical Faculty, University of Duisburg-Essen, Essen, Germany; ⁷Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany; ⁸Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; ⁹Department of Gastroenterology, General Hospital of Athens "Laiko", Medical School of National & Kapodistrian University of Athens, Greece; ¹⁰Institute of Liver Studies, King's College Hospital, London, UK; ¹¹Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Laboratory for Clinical and Experimental Hepatology, Leipzig, Germany; ¹²Department of Clinical and Experimental Medicine, University of Pisa and Hepatology Unit, University Hospital of Pisa, Pisa, Italy; ¹³Gastroenterology Department, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal; ¹⁴Department of Medical and Surgical Sciences, Unit of Infectious Diseases, "Alma Mater Studiorum" University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy; ¹⁵Department of Medical Sciences, University of Turin, Gastroenterology Division of Città della Salute e della Scienza of Turin, University Hospital, Turin, Italy; ¹⁶Lyon Hepatology Institute, Université Claude Bernard Lyon 1; Hospices Civils de Lyon; INSERM Unit 1052 - CRCL; Lyon, France; ¹⁷Department of Infectious Diseases, Karolinska University Hospital, and Karolinska Institutet, Stockholm, Sweden; ¹⁸Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; ¹⁹Liver Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy; ²⁰Service d'hépatogastro-entérologie, CHU Grenoble-Alpes, Grenoble, France; ²¹Department of Internal Medicine IV, Gastroenterology & Hepatology, Medical University of Heidelberg, Heidelberg, Germany; ²²Department of Medical and Surgical Sciences, Infectious Diseases Unit, University of Foggia, Foggia, Italy; ²³Department of Mental Health and Public Medicine - Infectious Diseases Unit, University of Campania Luigi Vanvitelli, Naples, Italy; ²⁴Liver Unit, San Camillo Hospital, Department of Transplantation and General Surgery, Rome, Italy; ²⁵Hepato-Biliary Center, AP-HP Hôpital Universitaire Paul Brousse, Paris-Saclay University, Research INSERM-Paris Saclay Unit 1193, Villejuif, France; ²⁶Hôpital de la Source Orleans, France; ²⁷Service d'Hépatogastro-entérologie CHU de Tours, France; ²⁸Department of Digestive Diseases, Hospices Civils de Lyon, Edouard Herriot hospital, France; ²⁹Claude Bernard Lyon 1 University, France; ³⁰AP-HP, Avicenne Hospital, Hepatology Department, F-93000 Bobigny, France; ³¹Centre Hospitalier Anecy Genevois, France; ³²Department of Hepatogastroenterology, CHU de Caen Normandie, Caen, France; ³³AP-HP, Avicenne hospital, Liver Unit, Sorbonne Paris Nord University, Bobigny, France; ³⁴Division of Hepatology, Ospedale San Giuseppe, Italy; ³⁵Gastroenterology, Hepatology and Transplantation Division, ASST Papa Giovanni XXIII, Bergamo, Italy; ³⁶Division of Hepatogastroenterology, Department of Precision Medicine, Università della Campania "Luigi Vanvitelli", Naples, Italy; ³⁷Division of Internal Medicine



and Center for Hemochromatosis, University of Modena and Reggio Emilia, Modena, Italy; ³⁷Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy; ³⁸Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ³⁹Department of Gastroenterology, CH d'Avignon, Avignon, France; ⁴⁰Department of Gastroenterology, Toulouse University Hospital, Toulouse, France; ⁴¹Université de Nantes, INSERM UIC 1413, Department of Infectious Diseases, CHU Hôtel Dieu, Nantes, France; ⁴²Université Paris Cité; Assistance Publique des Hôpitaux de Paris, Hôpital Cochin, Hepatology/Addictology department, Paris, France; ⁴³Assistance Publique des Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Service des Maladies Infectieuses et Tropicales, Paris, France; ⁴⁴CHU Dijon, Service d'Hépatogastroentérologie et oncologie digestive, Inserm EPICAD LNC-UMR1231, Université de Bourgogne-Franche Comté, Dijon, France; ⁴⁵Service d'hépatogastroentérologie, Centre Hospitalier Intercommunal, Créteil; ⁴⁶School of Medicine and Surgery University of Milano Bicocca; ⁴⁷CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ⁴⁸D-SOLVE consortium, an EU Horizon Europe funded project [No 101057917]

P25 Bulevirtide monotherapy prevents liver decompensation in patients with hcv-related cirrhosis: a case control study with propensity score weighted analysis

E. Degasperis¹, A. De Silvestri², M.P. Anolli³, D. Sambarino¹, M. Borghi¹, R. Perbellini¹, F. Facchetti¹, R. Soffredini¹, S. Monaco¹, V. De Ledinghen³, S. Metivier⁴, M. Jachs⁵, T. Reiberger⁵, G. D'Offizi⁶, C. Dietz-Fricke⁷, G. Papatheodoridis⁸, M.R. Brunetto⁹, G. Verucchi¹⁰, A. Ciancio¹¹, F. Zoulim¹², A. Mangia¹³, M.N. Hilleret¹⁴, T.A. Santantonio¹⁵, N. Coppola¹⁶, A. Pellicelli¹⁷, B. Roche¹⁸, X. Causse¹⁹, L. D'Alteroche²⁰, J. Dumortier²¹, N. Ganne²², F. Heluwaer²³, I. Ollivier²⁴, A. Loglio²⁵, A. Federico²⁶, F. Pileri²⁷, M. Maracci²⁸, M. Tonnini²⁹, J.P. Arpurt³⁰, K. Barange³¹, E. Billaud³², S. Pol³³, A. Gervais³⁴, A. Minello³⁵, I. Rosa³⁶, M. Puoti³⁷, P. Lampertico^{1,38,39}

¹Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ²Clinical Epidemiology and Biometry Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; ³Hepatology Department, Haut-Lévêque Hospital, Bordeaux, France; ⁴Hepatology Unit, CHU Rangueil, 31059, Toulouse, France; ⁵Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; ⁶Division of Infectious Diseases - Hepatology, Department of Transplantation and General Surgery, Istituto Nazionale per le Malattie Infettive "L. Spallanzani" IRCCS, Rome Italy; ⁷Department of Gastroenterology, Hepatology Infectious Diseases and Endocrinology at Hannover Medical School, Hannover, Germany; ⁸Department of Gastroenterology, General Hospital of Athens "Laiko", Medical School of National & Kapodistrian University of Athens, Greece; ⁹Department of Clinical and Experimental Medicine, University of Pisa and Hepatology Unit, University Hospital of Pisa, Pisa, Italy; ¹⁰Department of Medical and Surgical Sciences, Unit of Infectious Diseases, "Alma Mater Studiorum" University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy; ¹¹Department of Medical Sciences, University of Turin, Gastroenterology Division of Città della Salute e della Scienza di Turin, University Hospital, Turin, Italy; ¹²Hepatology Department, Université Claude Bernard Lyon 1; Hospices Civils de Lyon; INSERM Unit 1052 - CRCL; Lyon, France; ¹³Liver Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy; ¹⁴Service d'hépatogastro-entérologie, CHU Grenoble-Alpes, Grenoble, France; ¹⁵Department of Medical and Surgical Sciences, Infectious Diseases Unit, University of Foggia, Foggia, Italy; ¹⁶Department of Mental Health and Public Medicine - Infectious Diseases Unit, University of Campania Luigi Vanvitelli, Naples, Italy; ¹⁷Liver Unit, San Camillo Hospital, Department of Transplantation and General Surgery, Rome, Italy; ¹⁸Hepato-Biliary Center, AP-HP Hôpital Universitaire Paul Brousse, Paris-Saclay University, Research INSERM-Paris Saclay Unit 1193, Villejuif, France; ¹⁹Hôpital de la Source Orleans, France; ²⁰Service d'Hépatogastroentérologie CHU de Tours, France; ²¹Department of Digestive Diseases, Hospices Civils de Lyon, Edouard Herriot hospital, France; Claude Bernard Lyon 1 University, France; ²²AP-HP, Avicenne Hospital, Hepatology Department, F-93000 Bobigny, France; ²³Centre Hospitalier Annecy Genevois, 74000 Annecy, France; ²⁴Department of Hepatogastroenterology, CHU de Caen Normandie, Caen, France; ²⁵Gastroenterology, Hepatology and Transplantation Division, ASST Papa Giovanni XXIII, Bergamo, Italy; ²⁶Division of Hepatogastroenterology, Department of Precision Medicine, Università della Campania "Luigi Vanvitelli", Naples, Italy; ²⁷Division of Internal Medicine and Center for Hemochromatosis, University of Modena and Reggio Emilia, Modena, Italy; ²⁸Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy; ²⁹Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ³⁰Department of Gastroenterology, CH d'Avignon, Avignon, France; ³¹Department of Gastroenterology, Toulouse University Hospital, Toulouse, France; ³²Université de Nantes, INSERM UIC 1413, Department of Infectious Diseases, CHU Hôtel Dieu, Nantes, France; ³³Université Paris Cité; Assistance Publique des Hôpitaux de Paris, Hôpital Cochin, Hepatology/Addictology department, Paris, France; ³⁴Assistance Publique des Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Service des Maladies Infectieuses et Tropicales, Paris, France; ³⁵CHU Dijon, Service d'Hépatogastroentérologie et oncologie digestive, Inserm EPICAD LNC-UMR1231, Université de Bourgogne-Franche Comté, Dijon, France; ³⁶Service d'hépatogastroentérologie, Centre Hospitalier Intercommunal, Créteil; ³⁷School of Medicine and Surgery University of Milano Bicocca; ³⁸CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ³⁹D-SOLVE consortium, an EU Horizon Europe funded project [No 101057917]

P26 Results From an Integrated Analysis at Week 96: Continued Treatment of Early Virologic Non-responders or Partial Responders With Bulevirtide Monotherapy for Chronic Hepatitis Delta Leads to Improvement in Virologic and Biochemical Responses

P. Lampertico^{1,2}, H. Wedemeyer³, M.R. Brunetto^{4,5}, P. Bogomolov⁶, T. Stepanova⁷, M. Bourlière⁸, H. Fontaine⁹, G. M. Chee⁹, D. Manuilov⁹, Q. An⁹, A. H. Lau⁹, B. L. Da⁹, J. F. Flaherty⁹, R. C. Mercier⁹, C. Frenette⁹, A. Osinusi⁹, G. Sebastian Gherlan¹⁰, A. Streinu-Cercel¹¹, S. Zeuzem¹², M. Cornberg³, D. Roulot¹³, F. Zoulim¹⁴, S. Aleman¹⁵, and T. Asselah¹⁶

¹Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ²CRC "A.M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ³CRC "A.M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ⁴Clinic for Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; ⁵Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa; ⁶Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; ⁷M.F. Vladimirov Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; ⁸Clinic of Modern Medicine, Moscow, Russian Federation; ⁹Hôpital Saint Joseph, Marseille, France; ¹⁰Gilead Sciences, Inc., Foster City, CA, USA; ¹¹Dr. Victor Babes Foundation, University of Medicine and Pharmacy "Carol Davila" Bucharest, Bucharest, Romania; ¹²National Institute of Infectious Diseases Prof. Dr. Matei Bals, Bucharest, Romania; ¹³University Hospital Frankfurt, Frankfurt am Main, Germany; ¹⁴Université Sorbonne Paris Nord, Bobigny, France; ¹⁵Hospital Croix Rousee, Lyon, France; ¹⁶Department of Infectious Diseases, Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden; ¹⁷Hôpital Beaujon, Université de Paris, Clichy, France



P27 Efficacy and Safety of 144 Weeks of Bulevirtide 2 mg or 10 mg Monotherapy From the Ongoing Phase 3 Study MYR301

P. Lampertico^{1,2}, S. Aleman³, M. Brunetto^{4,5}, A. Blank⁶, P. Andreone⁷, P. Bogomolov⁸, V. Chulanov⁹, N. Mamonova⁹, N. Geyvandova¹⁰, M. Viacheslav¹¹, O. Sagalova¹², T. Stepanova¹³, G.M. Chee¹⁴, D. Manuilov¹⁴, M. Li¹⁴, A.H. Lau¹⁴, A. Osinusi¹⁴, J. Schulze zur Wiesch¹⁵, M. Cornberg¹⁶, S. Zeuzem¹⁷, H. Wedemeyer¹⁶

¹Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ²CRC "A.M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ³CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ⁴Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden; ⁵University Hospital of Pisa, Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, Pisa, Italy; ⁶Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; ⁷Department of Clinical Pharmacology and Pharmacoeconomics, Heidelberg University Hospital, Medical Faculty Heidelberg/Heidelberg University Hospital, Heidelberg, Germany; ⁸University of Modena and Reggio Emilia, Internal Medicine, Baggiovara Hospital, Modena, Italy; ⁹M.F. Vladimirovsky Moscow Regional and Clinical Institute, Moscow, Russian Federation; ¹⁰FSBI National Research Medical Center for Phthysiolpulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow, Russian Federation; ¹¹Stavropol Regional Hospital, Stavropol, Russian Federation; ¹²LLC Medical Company Hepatolog, Samara, Russian Federation; ¹³South Ural State Medical University, Chelyabinsk, Russian Federation; ¹⁴LLC Clinic of Modern Medicine, Moscow, Russian Federation; ¹⁵Gilead Sciences, Inc., Foster City, CA, USA; ¹⁶Hepatology Outpatient Medical Clinic, University Hospital Hamburg-Eppendorf, Hamburg, Germany; ¹⁷Clinic for Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; ¹⁸Department of Medicine, University Hospital Frankfurt, Frankfurt am Main, Germany

P28 Forty-Eight-Week Off-Therapy Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Patients With Chronic Hepatitis Delta: Final Results From the Phase 2b, Open-Label, Randomised, Multicentre Study MYR204

T. Asselah¹, V. Chulanov², P. Lampertico^{3,4}, H. Wedemeyer⁵, A. Streinu-Cercel⁶, V. Pantea⁷, S. Lazar⁸, G. Sebastian Gherlan⁸, P. Bogomolov⁹, T. Stepanova¹⁰, V. Morozov¹¹, V. Syutkin¹², O. Sagalova¹³, D. Manuilov¹⁴, R.C. Mercier¹⁴, L. Ye¹⁴, G.M. Chee¹⁴, B.L. Dai¹⁴, A.H. Lau¹⁴, A. Osinusi¹⁴, M. Bourlière¹⁵, V. Ratziu¹⁶, S. Pol¹⁷, M.N. Hilleret¹⁸ and F. Zoulim¹⁹

¹Hôpital Beaujon APHP, Université de Paris-Cité, INSERM UMR1149, Clichy, France; ²Sechenov University, Moscow, Russian Federation; ³Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ⁴CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ⁵Clinic for Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; ⁶National Institute of Infectious Diseases Prof. Dr. Matei Bals, Bucharest, Romania; ⁷Toma Ciorbă Infectious Diseases Clinical Hospital, Chişinău, Moldova; ⁸Dr. Victor Babes Foundation, University of Medicine and Pharmacy "Carol Davila" Bucharest, Bucharest, Romania; ⁹M.F. Vladimirovsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; ¹⁰LLC Clinic of Modern Medicine, Moscow, Russian Federation; ¹¹LLC Medical Company Hepatolog, Samara, Russian Federation; ¹²NV Sklifosovsky Institute of Emergency Medicine, Moscow, Russian Federation; ¹³South Ural State Medical University, Chelyabinsk, Russian Federation; ¹⁴Gilead Sciences, Inc., Foster City, CA, USA; ¹⁵Hôpital Saint Joseph, Marseille, France; ¹⁶CH Pitié-Salpêtrière, Paris, France; ¹⁷Hôpital Cochin, Paris, France; ¹⁸Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France; ¹⁹Hospital Croix Rousse, Lyon, France

P29 Treatment of chronic hepatitis D with bulevirtide: 1st year report

R. Rapetti,¹ M.G. Crobù,^{2,3} R. Minisini,¹ C. Smirne,¹ P. Ravanini,² M. Pirisi¹

¹Internal Medicine, Azienda Ospedaliero-Universitaria "Maggiore Della Carità", Novara, Italy. ²Department of Translational Medicine (DiMeT), Università del Piemonte Orientale, Novara, Italy; ³Laboratory of Molecular Virology, Maggiore della Carità Hospital, 28100 Novara; ⁴Clinical Biochemistry Laboratory, Department of Laboratory Medicine, City of Health and Science University Hospital, 10126 Turin, Italy

P30 Bulevirtide monotherapy in patients with compensated cirrhosis and CSPH: a 96-week interim kinetic analysis of real-life setting

O. Wasserman¹, L. Shekhtman^{1,2}, S.J. Cotler¹, E. Degasperis³, M.P. Anolli³, S. Colonia Uceda Renteria³, D. Sambarino³, M. Borghi³, R. Perbellini³, F. Facchetti³, F. Ceriotti⁴, H. Dahari¹, P. Lampertico^{3,5}

¹Program for Experimental & Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA; ²Department of Information Science, Bar-Ilan University, Ramat Gan, Israel; ³Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy; ⁴Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Virology Unit, Milan, Italy; ⁵CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

P31 Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the Phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants

T. Asselah¹, A. Streinu-Cercel², A. Jucov³, E. Gane⁴, H. Wedemeyer⁵, P. Lampertico^{6,7}, M.A. Chattergoon⁸, P. Wu⁸, S. Maciejewski⁸, C. Pilowa⁸, A. Hassani⁸, T. Correll⁸, C. Hwang⁸, K. Agarwal⁹

¹Université de Paris Cité, Hôpital Beaujon, AP-HP, INSERM UMR1149, Paris, France; ²National Institute for Infectious Diseases Matei Bals, Carol Davila University of Pharmacy and Medicine, Bucharest, Romania; ³Arensia Exploratory Medicine GmbH, Düsseldorf, Germany and Nicolae Testemitanu State University of Medicine and Pharmacy, Chişinău, Moldova; ⁴Auckland Clinical Studies, Auckland, New Zealand; ⁵Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany; ⁶Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ⁷CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ⁸Vir Biotechnology, Inc., San Francisco, CA; ⁹King's College Hospital, London, UK



P32 Improvement in Liver Histology Is Observed in Most Patients With Chronic Hepatitis Delta After 48 Weeks of Bulevir- tide Monotherapy

P. Lampertico^{1,2}, S. Aleman³, P. Bogomolov⁴, T. Stepanova⁵, M. Cornberg⁶, S. Ciesek⁷, A. Berger⁷, D. Manuilov⁸, M. Li⁸, A.H. Lau⁸, B.L. Da⁸, G.M. Chee⁸, M.R. Brunetto^{9,10}, S. Zeuzem¹¹, H. Wedemeyer⁶

¹Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ²Department of Pathophysiology and Transplantation, CRC "A. M. and A. Migliavacca" Center for Liver Disease, University of Milan, Milan, Italy; ³Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden; ⁴M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; ⁵LLC Clinic of Modern Medicine, Moscow, Russian Federation; ⁶Clinic for Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany; ⁷Institute for Medical Virology, German Centre for Infection Research, External Partner Site Frankfurt, University Hospital, Goethe University Frankfurt am Main, Frankfurt am Main, Germany; ⁸Gilead Sciences, Inc., Foster City, CA, USA; ⁹Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa and Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; ¹⁰Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; ¹¹Department of Medicine, University Hospital Frankfurt, Frankfurt am Main, Germany

P33 Rapid reductions of HDV RNA and ALT with the monoclonal antibody, BJT-778: results from a phase 2 study

K. Agarwal¹, M. Dobryanska², A. Jucov³, P. Kennedy⁴, E.J. Gane⁵, M.F. Yuen⁶, G. Lai-Hung Wong⁷, S. Strasser⁸, J. Holmes⁹, S. Roberts¹⁰, H. Javanbakht¹¹, J. Stanton¹¹, N. Shulman¹¹

¹Kings College Hospital, London, United Kingdom; ²ARENIA Exploratory Medicine, Kyiv, Ukraine; ³ARENIA Exploratory Medicine, Chisinau; ⁴Queen Mary University Hospital, London, United Kingdom; ⁵New Zealand Clinical Research, University of Auckland, Auckland, New Zealand; ⁶Queen Mary University Hospital, Hong Kong, Hong Kong; ⁷Prince of Wales Hospital, Hong Kong, Hong Kong; ⁸Royal Prince Alfred Hospital, Sydney, Australia; ⁹St. Vincent's Hospital, Melbourne, Australia; ¹⁰The Alfred Hospital, Melbourne; ¹¹Bluejay Therapeutics, Inc., San Mateo, United States

P34 Treatment of chronic hepatitis delta with bulevirtide in Portugal: data from a real-life cohort

M.F. Cardoso¹, F. Calinas², C. Fonseca³, C. Gouveia⁴, A.A. Horta⁵, A. M. Vieira⁶, M. Machado⁷, C. Palmela⁴, J. Branco¹, G. Alexandrino¹, A. Martins¹
¹Gastroenterology Department, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal; ²Gastroenterology Department, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal; ³Gastroenterology Department, Hospital Garcia de Orta, Almada, Portugal; ⁴Gastroenterology Department, Hospital Beatriz Ângelo, Loures, Portugal; ⁵Infectious Diseases Department, Centro Hospitalar do Porto, Porto, Portugal; ⁶Gastroenterology Department, Centro Hospitalar Universitário do Algarve, Portimão, Portugal; ⁷Gastroenterology Department, Hospital de Vila Franca de Xira, Vila Franca de Xira, Portugal

P35 Detection and characterization of anti-preS1 antibodies in HDV-infected patients under Bulevir- tide treatment

Y. Aronhipaitoon¹, N. Szerman¹, E. Roch¹, F. Zoulim², C. Sureau¹, C. Gaudy-Graffin¹, and the ANRS HDEP01 Buldelta study group²
¹INSERM U1259, Morpogènèse et Antigénicité du VIH, des Virus des Hépatites et Émergents, Université de Tours, France; ²Service d'hépatologie et gastro-entérologie, HCL, Hôpital de la Croix Rousse, Lyon; France

P36 Treatment of HDV infection in Solid Organ Transplant with Bulevir- tide: a case report

B. Pinchera, A. d'Agostino, E. Trucillo, F. Cuccurullo, A.R. Buonomo, I. Gentile
Federico II Naples, Infectious Disease Department

P37 Patient-Reported Outcomes Among Patients With Chronic Hepatitis Delta Treated With Bulevir- tide 2 mg: A Long- Term Analysis of the Phase 3 MYR301 Trial at 96 Weeks

M. Buti^{1,2}, H. Wedemeyer³, S. Aleman⁴, V. Chulanov⁵, V. Morozov⁶, O. Sagalova⁷, T. Stepanova⁸, R. G. Gish^{9,10}, A. Lloyd¹¹, V. Suri¹², D. Manuilov¹², G. M. Chee¹², A. O. Osinusi¹², J. F. Flaherty¹², M. Rock¹², C. Kim¹², S. Pandey¹³, B. Singh¹³, and P. Lampertico^{14,15}

¹Liver Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain; ²Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBER-EHD) del Instituto Carlos III, Barcelona, Spain; ³Clinic for Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; ⁴Department of Infectious Diseases, Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden; ⁵Department of Infectious Diseases, Sechenov University, Moscow, Russian Federation; ⁶LLC Medical Company Hepatolog, Samara, Russian Federation; ⁷South Ural State Medical University, Chelyabinsk, Russian Federation; ⁸LLC Clinic of Modern Medicine, Moscow, Russian Federation; ⁹Robert G. Gish Consultants, LLC, San Diego, CA, USA; ¹⁰Hepatitis B Foundation, Doylestown, PA, USA; ¹¹Acaster Lloyd Consulting Ltd., London, UK; ¹²Gilead Sciences, Inc., Foster City, CA, USA; ¹³Pharmacoevidence Private Limited, Punjab, India; ¹⁴Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ¹⁵CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

P38 Real life experience of HBV/HDV-related compensated cirrhosis treatment in an Italian prison. A case report.

G. Quartini¹, C. Di Giulii¹, A. Lavagna¹, A. Marozzo³, D. Francisci².
¹Infectious Disease Clinic, Ospedale Santa Maria Terni, Università degli Studi di Perugia, Terni; ²Infectious Disease Clinic, Ospedale Santa Maria della Misericordia, Università degli Studi di Perugia, Perugia; ³Penitentiary medicine, Italian prison in Terni, Umbria

P39 Undetectable HDV RNA at 24 Weeks of Treatment With Bulevir- tide and Pegylated Interferon Alfa-2a Combination Therapy Is an Important Predictor of Maintained Response Off-Therapy

F. Zoulim¹, V. Chulanov², P. Lampertico^{3,4}, H. Wedemeyer⁵, A. Streinu-Cercel^{6,7}, V. Pantea⁸, S. Lazar⁹, G.S. Gherlan¹⁰, P. Bogomolov¹¹, T. Stepanova¹², V. Morozov¹³, V. Syutkin¹⁴, O. Sagalova¹⁵, D. Manuilov¹⁶, R.C. Mercier¹⁶, L. Ye¹⁶, G.M. Chee¹⁶, B.L. Da¹⁶, A.H. Lau¹⁶, A. Osinusi¹⁶, M. Bourlière¹⁷, V. Ratziu¹⁸, S. Pol¹⁹, M.N. Hilleret²⁰, T. Asselah²¹

¹Hospital Croix Rousse, Hospices Civils de Lyon, INSERM, Université Claude Bernard Lyon 1, Lyon, France; ²Sechenov University, Moscow, Russian Federation; ³Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy; ⁴CRC "A. M. and A. Migliavacca" Center for Liver Disease, University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy; ⁵Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Germany; ⁶Matei Bals National Institute of Infectious Diseases, Bucharest, Romania; ⁷Carol



Davila" University of Medicine and Pharmacy, Bucharest, Romania; ⁸Infectious Clinical Hospital "T. Ciorba," Chisinau, Moldova; ⁹Dr. Victor Babes Foundation, Infectious and Tropical Diseases Hospital, Bucharest, Romania; ¹⁰Dr. Victor Babes Foundation, Bucharest, Romania; ¹¹M.F. Vladimirovsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; ¹²LLC Clinic of Modern Medicine, Moscow, Russian Federation; ¹³LLC Medical Company "Hepatolog," Samara, Russian Federation; ¹⁴Institute of Emergency Medicine n.a. NV Sklifosovsky, Moscow, Russian Federation; ¹⁵South Ural State Medical University, Chelyabinsk, Russian Federation; ¹⁶Gilead Sciences, Inc., Foster City, CA, USA; ¹⁷Hôpital Saint Joseph, Marseille, France; ¹⁸CH Pitié-Salpêtrière, Paris, France; ¹⁹Hôpital Cochin, Paris, France; ²⁰Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France; ²¹Hôpital Beaujon APHP, Université de Paris-Cité, INSERM, Clichy, France

P40 Undetectable HDV RNA Defined as Target Not Detected at the End of Treatment With Bulevirtide and/or Pegylated Interferon Alpha-2a Is an Important Predictor of 48 Weeks Sustained Virologic Response in Chronic Hepatitis Delta

F. Zoulim¹, T. Asselah², V. Chulanov³, A. Streinu-Cercel^{4,5}, G.S. Gherlan^{5,6}, P. Bogomolov⁷, T. Stepanova⁸, V. Morozov⁹, O. Sagalova¹⁰, R.C. Mercier¹¹, L. Ye¹¹, D. Manuilov¹¹, A.H. Lau¹¹, G.M. Chee¹¹, B.L. Da¹¹, M. Bourlière¹², H. Wedemeyer¹³, P. Lampertico^{14,15}
¹Hospital Croix Rousse, Lyon, France; ²Hôpital Beaujon APHP, Université de Paris, INSERM, Clichy, France; ³Sechenov University, Moscow, Russian Federation; ⁴Matei Bals National Institute of Infectious Diseases, Bucharest, Romania; ⁵Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania; ⁶Dr. Victor Babes Foundation, Bucharest, Romania; ⁷M.F. Vladimirovsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; ⁸LLC Clinic of Modern Medicine, Moscow, Russian Federation; ⁹LLC Medical Company "Hepatolog," Samara, Russian Federation; ¹⁰South Ural State Medical University, Chelyabinsk, Russian Federation; ¹¹Gilead Sciences, Inc., Foster City, CA, USA; ¹²Hôpital Saint Joseph, Marseille, France; ¹³Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Germany; ¹⁴Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ¹⁵Department of Pathophysiology and Transplantation, CRC "A. M. and A. Migliavacca" Center for Liver Disease, University of Milan, Milan, Italy

P41 High Rates of Adherence to Bulevirtide Monotherapy for Chronic Hepatitis Delta Through 96 Weeks: Results From an Interim Analysis of the Phase 3 Study MYR301

S. Aleman¹, H. Wedemeyer², M.R. Brunetto^{3,4}, A. Blank⁵, P. Andreone⁶, P. Bogomolov⁷, V. Chulanov⁸, N. Mamonova⁸, N. Geyvandova⁹, V. Morozov¹⁰, O. Sagalova¹¹, T. Stepanova¹², B.L. Da¹³, D. Manuilov¹³, G.M. Chee¹³, M. Li¹³, A.H. Lau¹³, J. Schulze zur Wiesch¹⁴, M. Cornberg², S. Zeuzem¹⁵, P. Lampertico^{16,17}
¹Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden; ²Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hannover, Germany; ³Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Pisa, Italy; ⁴Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; ⁵Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany; ⁶Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy; ⁷State Budgetary Institution of Health Care of Moscow Region "Moscow Regional Research Clinical Institute Named After M.F. Vladimirovsky," Moscow, Russian Federation; ⁸FSBI National Research Medical Center for Phthisiopulmonology and Infectious Diseases, Moscow, Russian Federation; ⁹Stavropol Regional Hospital, Stavropol, Russian Federation; ¹⁰LLC Medical Company "Hepatolog," Samara, Russian Federation; ¹¹South Ural State Medical University, Chelyabinsk, Russian Federation; ¹²LLC Clinic of Modern Medicine, Moscow, Russian Federation; ¹³Gilead Sciences, Inc., Foster City, CA, USA; ¹⁴Universitätsklinikum Hamburg-Eppendorf Medizinische Klinik Studienambulanz Hepatologie, Hamburg, Germany; ¹⁵Department of Medicine, University Hospital Frankfurt, Frankfurt am Main, Germany; ¹⁶Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ¹⁷Department of Pathophysiology and Transplantation, CRC "A.M. and A. Migliavacca" Center for Liver Disease, University of Milan, Milan, Italy

P42 Improvements in Fibrosis and Necroinflammation With Bulevirtide Combined With Pegylated Interferon for Chronic Hepatitis Delta

D. Roulot¹, F. Zoulim², V. Chulanov³, V. Pantea⁴, S. Lazar⁵, G. Placinta⁶, G.S. Gherlan^{7,8}, P. Bogomolov⁹, T. Stepanova¹⁰, V. Morozov¹¹, V. Syutkin¹², O. Sagalova¹³, R.C. Mercier¹⁴, D. Manuilov¹⁴, L. Ye¹⁴, D. Tedesco¹⁴, M. Bourlière¹⁵, M.N. Hilleret¹⁶, T. Asselah¹⁷
¹AP-HP, Hôpital Avicenne, Unité d'hépatologie, Université Paris 13, Bobigny; Inserm U955, équipe 18, Université Paris-Est, Créteil; ²Hospices Civils de Lyon, Université Claude Bernard Lyon 1, INSERM Unit 1052, Lyon Hepatology Institute, Lyon, France; ³Sechenov University, Infectious Diseases Department, Moscow, Russian Federation; ⁴Infectious Clinical Hospital "T. Ciorba," Chisinau, Moldova; ⁵Dr. Victor Babes Foundation, Infectious and Tropical Diseases Hospital, Bucharest, Romania; ⁶State University of Medicine and Pharmacy "Nicolae Testemitanu," Infectious Clinical Hospital "T. Ciorba," Chisinau, Moldova; ⁷Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ⁸Dr. Victor Babes Foundation, Bucharest, Romania; ⁹M.F. Vladimirovsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; ¹⁰LLC Clinic of Modern Medicine, Moscow, Russian Federation; ¹¹LLC Medical Company "Hepatolog," Samara, Russian Federation; ¹²Institute of Emergency Medicine n.a. NV Sklifosovsky, Moscow, Russian Federation; ¹³South Ural State Medical University, Chelyabinsk, Russian Federation; ¹⁴Gilead Sciences, Foster City, CA, USA; ¹⁵Hôpital Saint Joseph, Marseille, France; ¹⁶Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France; ¹⁷Université de Paris-Cité, Department of Hepatology, Hôpital Beaujon AP-HP, Centre de Recherche sur l'Inflammation, INSERM UMR1149, Clichy, France

P43 Efficacy and safety of BLV monotherapy for chronic hepatitis delta: post treatment results through 24 weeks after the end of treatment from an interim analysis of a randomized Phase 3 study MYR301

S. Aleman¹, P. Lampertico^{2,3}, M. Brunetto^{4,5}, P. Bogomolov⁶, V. Chulanov⁷, T. Stepanova⁸, A. Lichtman⁹, R.C. Mercier⁹, D. Manuilov⁹, S. Arterburn⁹, A. Osinusi⁹, F. Christian-Cox⁹, M. Cornberg¹⁰, S. Zeuzem¹¹, H. Wedemeyer¹²
¹Karolinska University Hospital/Karolinska Institutet, Department of Infectious Diseases, Stockholm, Sweden, Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore, ²Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ³CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, ⁴University Hospital of Pisa, Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, Pisa, Italy, ⁵University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy, ⁶State Budgetary Institution of Health Care of Moscow Region "Moscow Regional Research Clinical Institute Named After M.F. Vladimirovsky," Moscow, Russian Federation, ⁷Sechenov University, Moscow, Russian Federation, ⁸Limited Liability Company "Clinic of Modern Medicine," Moscow, Russian Federation, ⁹Gilead Sciences, Inc., Foster City, United States, ¹⁰Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie, Infektiologie und Endokrinologie, Hannover, Germany, ¹¹Department of Medicine, University Hospital, Goethe-University, Frankfurt, Germany, ¹²Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie, Infektiologie und Endokrinologie, Hannover, Germany, RESIST, DZIF and D-Solve



POSTER AREA 3 - VIROLOGY AND PATHOGENESIS

P44 HIV-HBV-HDV co-infection. Case presentation.

M.N. Radu¹, C. Tudoran¹, R.B. Băloiu¹, F.A. Căruntu^{1,2}

¹Department Adults 1, National Institute for Infectious Diseases "Prof. Dr. Matei Bals"(INBIMB), Bucharest; ²Department of Infectious Disease, University of Medicine and Pharmacy "Carol Davila", Bucharest

P45 Differential patterns of HBV rna and HBcrAG levels in a large european cross-sectional study of untreated patients with chronic hepatitis delta

E. Degasperis¹, C. Scholtes^{2,3,4,5}, B. Testoni^{3,4,5}, S. Uceda Renteria⁶, M.P. Anolli¹, C. Charre^{7,8}, F. Facchetti¹, M.L. Plissonnier^{3,4,5}, D. Sambarino¹, R. Perbellini¹, S. Monaco¹, A. Callegaro⁶, E. García-Pras⁹, S. Lens⁹, M.F. Cortese¹⁰, X. Forn⁹, S. Pérez-del-Pulgar⁹, M. Heil¹¹, M. Levrero^{3,4,5,12,13}, F. Zoulim^{3,4,5,13}, P. Lampertico^{1,14,15}

¹Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ²Virology Department, Hospices Civils de Lyon (HCL) and Université Claude Bernard Lyon 1 (UCBL1), Lyon, France; ³INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, France; ⁴University of Lyon, Université Claude-Bernard (UCBL), Lyon, France; ⁵The Lyon Hepatology Institute (IHU EVEREST), Lyon, France; ⁶Microbiology and Virology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ⁷INSERM U1016, CNRS, UMR8104, Paris France; ⁸Virology Department, Hôpital Cochin, APHP, Paris France; ⁹Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain; ¹⁰Liver unit, Group of Microbiology, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, CIBEREHD, Barcelona, Spain; ¹¹Roche Molecular Diagnostics, Pleasanton, California, USA; ¹²Department of Internal Medicine, SClAC and the IIT Center for Life Nanoscience, Sapienza University, Rome, Italy; ¹³Hepatology Department, Hospices Civils de Lyon (HCL); ¹⁴CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ¹⁵D-SOLVE consortium, an EU Horizon Europe funded project (No 101057917)

P46 HELZ2 is an interferon stimulated gene with antiviral properties against Hepatitis Delta Virus

C. Authier¹, C. Eber², R. Fouillé¹, C. Bach², C. Pons¹, E. Charles², E. Huntzinger³, M. Rivoire⁴, G. Passot⁵, M. Michelet⁶, M. Oudot², T.F. Baumert², A. Salvetti¹, B. Seraphin³, D. Durantel¹, E. Verrier² and J. Lucifora¹

¹CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France; ²Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMR_S1110, Strasbourg, France; ³IGBMC, Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS UMR 7104, Inserm U 1258, Université de Strasbourg, Illkirch, France; ⁴Centre Léon Bérard (CLB), INSERM, U1032, Lyon, France; ⁵Service de chirurgie générale et oncologique, Hôpital Lyon Sud, Hospices Civils de Lyon Et CICLY, EA3738, Université Lyon 1; ⁶INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard, Lyon, France

P47 Hospitalised Adults With Hepatitis Delta Virus Infection Have Higher Risk of Disease Progression Than Those With Hepatitis B Virus Mono-infection in Italy

P. Lampertico^{1,2}, V. Perrone³, L. Degli Esposti³, M. Leogrande³, C. Kim⁴, and M. Rock⁴

¹Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ²CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ³CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, Bologna, Italy; ⁴HEOR – Global Value & Access, Gilead Sciences, Inc., Foster City, CA, USA

P48 Baseline characteristics and risk of liver-related events in hepatitis B and C coinfection with and without hepatitis D infection

L.E. Telep¹, A.W. Singer¹, K.M. Kwon¹, A.E. Stead¹, A.P. Chokkalingam¹

Gilead Science, Foster City, CA, USA

P49 TIGIT-expression on natural killer cell subsets correlate with liver inflammation and bulevirtide treatment response in chronic hepatitis D

P.C. Chen^{1,4}, K. Deterding¹, S.A.Engelskircher¹, M. Cornberg^{1,2,3,6}, A. Kraft^{1,2}, N.K Björkstöm⁵, N. Woller^{1,2}, and H. Wedemeyer^{1,2,3}

¹Department of Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover; ²German Center for Infection Research (DZIF), partner site Hannover-Braunschweig; ³Cluster of Excellence RESIST, Hannover Medical School, Hannover; ⁴ZIB program, Hannover Medical School, Hannover; ⁵Center of Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm; ⁶Centre for Individualized Infection Medicine (CIIM), Hannover

P50 Adenine Base editing of Hepatitis B surface antigen potently inhibits HDV

A. Kumar^{1,2,3}, E. Combe^{1,2,3}, E.M. Smekalova⁴, S. Dejene⁴, C-Y. Chen¹, L. Mougené^{1,2,3}, M.G. Martinez¹, G. Ciaramella⁴, M.S. Packer⁴, B. Testoni^{1,2,3}, F. Zoulim^{1,2,3,5}

¹INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon, Lyon, France; ²University of Lyon, Université Claude-Bernard (UCBL), Lyon, France; ³The Lyon Hepatology Institute EVEREST, Lyon, France; ⁴Beam Therapeutics, Cambridge, MA, USA; ⁵Department of Hepatology, Croix Rousse hospital, Hospices Civils de Lyon, Lyon, France

P51 Sequence Analysis of the Hepatitis D Virus (HDV) Across Genotypes shows Highly Conserved Regions and Evidence of Recombination

S. Chowdhury^{1,2}, C. Jacobsen^{1,2}, D. Depledge^{2,4,5}, H. Wedemeyer^{1,2,3,4}, L. Sandmann^{1,2,3} and H. Kefalakes^{1,2,3,4}

¹Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; ²Cluster of Excellence RESIST, EXC-2155, Hannover Medical School, Hannover, Germany; ³European D-SOLVE Consortium; ⁴German Center for Infection Research, Partner Site Hannover-Braunschweig; ⁵Institute of Virology, Hannover Medical School, Hannover, Germany



- P52 Deciphering the cellular response to IFN treatment in HDV-infected cells**
C. Eberl¹, R. Fouillé², E. Gerges¹, T.F. Baumert^{1,3,4}, D. Durantel², J. Lucifora², E.R. Verrier¹
¹University of Strasbourg, Inserm, Institute for Translational Medicine and Liver Disease (ITM), UMR_S1110, Strasbourg; ²CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France; ³Institut hospitalo-universitaire (IHU), Service d'hépatogastroentérologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; ⁴Institut Universitaire de France (IUF), Paris, France
- P53 Epidemiology and natural history of chronic hepatitis B and D infections in France from 2013 to 2022**
T. Asselah¹, V. Loustaud-Ratti², J.P. Bronowicki³, E. Maugain⁴, A. Le Blevec⁴, C. Idelovici-Marchal⁴, C. Lacueille⁵, E. Lambourg⁵, S. Larrieu⁵, Charlotte Colombi⁴
¹Hôpital Beaujon Clichy - France, ²CHU Limoges - France, ³CHU Nancy - France, ⁴Gilead Sciences, ⁵Horiana Bordeaux - France
- P54 Healthcare Resource Utilisation and Costs Among Terminal, Hospitalised Adults With Hepatitis Delta Virus or Hepatitis B Virus Mono-infection in Italy**
P. Lampertico^{1,2}, V. Perrone³, L.D. Esposito³, M. Leogrande³, C. Kim⁴, M. Rock⁴
¹CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ²Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy; ³CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, Bologna, Italy; ⁴HEOR - Global Value & Access, Gilead Sciences, Inc., Foster City, CA, USA
- P55 Rational immunotherapy design for clinical development against HDV using a synthetic DNA-prime and protein-boost strategy**
G. Ahlén¹, L. Frelin¹, J. Yan¹, C. Bin Ahn Nordström¹, P. Cunnah², A. Ricardo², N. Mertens³, R. Bethell⁴, and M. Sällberg¹
¹Karolinska Institutet, Stockholm; ²Rodon Biologics, Oeiras; ³Bionmer, Antwerpen
- P56 Development of a rapid test for HDV-specific T cell characterization in whole blood**
N. Le Bert¹, F. Facchetti², A.T. Tan¹, M.P. Anolli², S. Hariharaputran¹, S.K. Hang¹, E. Degasperis², A. Bertoletti¹, P. Lampertico^{2,3}
¹Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; ²Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ³CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Italy
- P57 HDV persistence can be independent from the extent of HBV reservoir and can be sustained by HBsAg production mainly derived from HBV-DNA integration**
S. D'Anna¹, L. Piermatteo¹, G. Brancaccio², E. Teti³, A. Di Lorenzo³, I. Grossi¹, G. Torre¹, V. Malagnino³, M. Iannetta³, F. Ceccherini-Silberstein⁴, C. Pasquazzi⁵, U. Cillo⁶, A. Vitale⁶, E. Gringeri⁶, M. Magrofuoco⁶, M. Pacenti⁷, L. Baiocchi⁸, S. Francioso⁸, I. Lenci⁸, A. Koffas⁹, A.M. Geretti¹⁰, M. L. Abate¹¹, A. Olivero¹¹, G. B. Gaeta¹², L. Sarmati³, M. Rizzetto¹¹, U. Gill⁹, P. Kennedy⁹, G. P. Caviglia¹¹, V. Svircher¹, R. Salpini¹
¹Department of Biology, Tor Vergata University, Rome, Italy; ²Department of Molecular Medicine, Infectious Diseases, University of Padua, Padua, Italy; ³Infectious Diseases Unit, University Hospital of Rome Tor Vergata, Rome, Italy; ⁴Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy; ⁵Sant'Andrea Hospital, Rome, Italy; ⁶Hepatobiliary Surgery, Oncology and Gastroenterology, Department of Surgery, University of Padova, Padua, Italy; ⁷Microbiology and Virology Unit, Padova University Hospital, Padua, Italy; ⁸Hepatology Unit, Policlinico Tor Vergata, Rome, Italy; ⁹Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; ¹⁰Department of Systems Medicine, Infectious Disease Clinic, University of Rome Tor Vergata, Rome, Italy; ¹¹Department of Medical Sciences, University of Turin, Turin, Italy; ¹²Infectious Disease Unit, University L. Vanvitelli, Naples, Naples, Italy
- P58 Low expression of circulating liver-enriched miRNAs in anti-HDAG patients in absence of active viral replication.**
M.F. Cortese^{1,2}, J. Pérez Garreta¹, B. Pacin Ruiz¹, A. Palom^{2,4}, D. Taberner^{1,2}, A. Rando Segura^{1,2,4}, E. Vargas Accarino^{2,3}, J.C. Ruiz Cobo^{2,3}, M. Riveiro Barciela^{2,3,5}, M. Buti^{2,3,5}
¹Microbiology, Liver unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; ²Instituto de Salud Carlos III, Centro de investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; ³Department of hepatology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; ⁴Department of Microbiology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; ⁵Universitat Autònoma de Barcelona, Bellaterra, Spain
- P59 Real world patient profile for individuals with hepatitis delta virus infection treated with bulevirtide 2mg in Europe**
L.E. Telep¹, C. Kim¹, K.M. Kwon¹
Gilead Sciences, Foster City, CA, USA
- P60 High diversity of the TCR repertoire in hepatitis delta virus patients with undetectable viral RNA**
M.F. Cortese^{1,2}, A. Palom^{2,3}, B. Pacin Ruiz^{1,2}, F. Rudilla^{4,4}, E. Enrich Randé^{4,5}, M. Antón Iborra⁵, J.C. Ruiz-Cobo^{2,3}, D. Taberner^{1,2,6}, M. Riveiro Barciela^{3,7}, A. Rando-Segura^{1,2,8,9}, M.J. Herrero^{4,5}, M. Buti^{2,3,7}
¹Department of microbiology, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; ²Carlos III Health Institute, Network Center For Biomedical Research in Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain; ³Department of Hepatology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; ⁴Histocompatibility and Immunogenetics Laboratory, Banc de Sang i Teixits, Barcelona, Spain; ⁵Transfusional Medicine Group, Vall d'Hebron Research Institute- Universitat Autònoma de Barcelona, Barcelona, Spain; ⁶Liver Disease, Viral hepatitis laboratory, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; ⁷Universitat autònoma de Barcelona (UAB), Barcelona, Spain; ⁸Department of Microbiology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain

- P61 Dichotomy between HBcrAg and pre-genomic HBV RNA in relation to HDV RNA response in patients with chronic hepatitis delta during bulevirtide treatment**
Z. Cargill¹, M. Andreson², J. Lok¹, S. Shah¹, G. Cloherty², G. Dusheiko¹, K. Agarwal¹, I. Carey¹
¹Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, United Kingdom; ²Department of Infectious Diseases, Abbott Diagnostics, North Chicago, Illinois, United States of America
- P62 Plasma pre-S1 HBsAg levels during antiviral therapy with Bulevirtide in chronic hepatitis delta patients – any help in predicting response to therapy?**
Z. Cargill¹, M. Anderson², J. Lok¹, S. Shah¹, G. Cloherty², G. Dusheiko¹, K. Agarwal¹, I. Carey¹
¹Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, United Kingdom; ²Department of Infectious Diseases, Abbott Diagnostics, North Chicago, Illinois, United States of America
- P63 HDV co-infection and HCV eradication in persons with HIV (PWH): data from the ICONA cohort**
A. Tavelli¹, R. Rossotti², V. Malagnino³, V. Svicher⁴, E. Quiros-Roldan⁵, A. Bandera⁶, F.M. Fusco⁷, M. Rivano Capparuccia⁸, G.B. Gaeta⁹, A. Antinori¹⁰, M. Puoti², A d'Arminio Monforte¹
¹ICONA Foundation, Milan, Italy; ²Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Ca' Granda Hospital, Milan, Italy; ³Department of Medicine of Systems, University of Rome Tor Vergata, Rome, Italy; ⁴Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy; ⁵University of Brescia and ASST Spedali Civili of Brescia, Department of Infectious and Tropical Diseases, Brescia, Italy; ⁶Infectious Disease Unit, Department of Internal Medicine, Fondazione IRCCS Ca, Granda, Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milano Milan, Italy; ⁷UOC Infezioni Sistemiche e dell'Immunodepresso, AORN Ospedali dei Colli, P.O. "D. Cotugno", Naples, Italy; ⁸Infectious and Tropical Disease Unit, Policlinico Umberto I, Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy; ⁹University L. Vanvitelli, Infectious Diseases Unit, Naples, Italy; ¹⁰Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- P64 Role of intrahepatic HDV reservoir in potentially modulating response to bulevirtide treatment at 24 weeks.**
A. Di Lorenzo^{1,2}, S. D'Anna³, D. Kontogiannis², C. Sorace², A. Crea², E. Teti², V. Malagnino², L. Piermatteo³, I. Grossi³, C. Castelli³, M. Nezzo⁴, B. Carreri⁴, A.M. Geretti^{1,2}, V. Svicher³, R. Salpini³, L. Sarmati^{1,2}
¹Tor Vergata University, Via Montpellier, 1 - 00133 Rome, Italy; ²Department of Systems Medicine, Infectious Disease Clinic, Viale Oxford, 81- 00133 Rome, Italy; ³Department of Biology, University of Rome Tor Vergata; ⁴Department of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, Rome, Italy
- P65 Integrative transcriptomics and epigenomics reveals a viral footprint of chronic HDV infection in HBV co-infected chimeric livers**
Y. Simanjuntak¹, T.F. Baumert^{1,2,3,4}, J. Lupberger¹ and the D-Solve consortium
¹University of Strasbourg, Institute of Translational Medicine and Liver Diseases (ITM), Inserm UMR_S1110, Strasbourg, France; ²Gastroenterology and Hepatology Service, Strasbourg University Hospitals, France; ³Institut Universitaire de France, Paris, France; ⁴IHU Strasbourg, France
- P66 Adaptive immunity may drive treatment outcome of pegylated IFN alpha in patients with chronic hepatitis D**
M. Anim^{1,2}, L. Sandmann^{1,2,3,4}, B. Bremer¹, H. Wedemeyer^{1,2,3,4} and H. Kefalakes^{1,2,3,4} on behalf of the HIDIT-II study group
¹Dept. of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, ²D-SOLVE Consortium, ³Cluster of excellence RESIST (EXC-2155), ⁴German Center for Infection Research, Partner Site Hannover-Braunschweig (DZIF)



CONGRESS VENUE

Fondazione Cariplo - Conference Center

Via Romagnosi, 8 - 20121 Milan, Italy

<https://www.centrocongressifondazionecriplo.it/en/>

How to reach Fondazione Cariplo Conference Center

The Congress Venue is very well connected to the city centre, railway stations and airports



UNDERGROUND

- M1 (Red line) - Duomo stop
- M3 (Yellow line) - Montenapoleone stop



BUS

- n.85
Montenapoleone stop

Congress website: www.deltacure2024.com

Official language: English, no simultaneous translation provided

INSTRUCTIONS FOR SPEAKERS

All presentations have to be handed over at the **Slide Center Room** at least **2 hours before the session**.

It will not be possible to connect one's own PC for the presentation. **Slide template** for Speakers' presentations is available for download on the Conference website www.deltacure2024.com

At the Slide Center Room, Speakers will have the possibility of:

- Reviewing PowerPoint presentations
- Last minute changes of PowerPoint presentations
- Being supported by technical staff

All Speakers are requested to start their presentation with a Disclosure of Potential Conflicts of Interest slide.

POSTER4YOU INSTRUCTIONS

Posters can be collected at the **"Poster4you" corner** at the meeting venue, on **October 11th from 11.00am to 12.00pm**.

The Presenting Author will be responsible for mounting the poster in the Poster Exhibition Area.

Each Presenting Author is responsible for his/her poster during Poster Sessions, scheduled on October 11th from 12.30 to 13.30 and from 15.20 to 15.50 and on October 12th from 11.00 to 11.30.

The posters will be uploaded on the Web Repository of the event and on the USB pen drive that can be collected at the Altona booth.



ACCREDITATIONS

CME accreditation

The meeting has been accredited to the Italian Ministry of Health - ID 150-416939 - for 9 CME credits for the following disciplines: Physicians: Allergology and Clinical Immunology; Hematology; Gastroenterology; Infectious and Tropical Diseases; Internal Medicine; Microbiology and Virology; Clinical Pathology; Hygiene, Epidemiology and Public Health; Hospital Medical Direction; Epidemiology; Biologists; Biomedical Laboratory Technicians; Hospital Pharmacists.

To obtain Italian CME credits participants must attend at least 90% of sessions and respond correctly to at least 75% of the questions included in the final evaluation questionnaire that will be available on-line at the end of the event from October 12th at 18.00pm to October 15th at 18.00pm (only one attempt allowed).

EACCME accreditation

The meeting is in the process of assessment for accreditation by the European Accreditation Council for Continuing Medical Education (EACCME®).

EthicalMedTech accreditation

The meeting is in the process of assessment for accreditation by MedTech Europe.

CME PROVIDER & PCO

Effetti srl

Via G.B. Giorgini 16 - 20151 Milan, Italy

Tel. +39 02 3343281 - Fax +39 02 38002105

E-mail: deltacure2024@effetti.it

Ref.: Elena Fiore - E-mail: elena.fiore@effetti.it

www.deltacure2024.com



OCTOBER
11-12, 2024
MILAN, ITALY

DeltaCure

3rd International Meeting

THANKS TO THE SPONSORS

The Chairs and the CME Provider wish to thank the following Companies for the support given to the Meeting, as unrestricted educational grants:

Platinum



Bronze



Co-sponsors

